CTIC - CTI BioPharma Corp.
| Previous Close | 1.0100 |
| Open | 1.0000 |
| Bid | 0.9400 x 1000 |
| Ask | 1.0600 x 1800 |
| Day's Range | 0.9600 - 1.0400 |
| 52 Week Range | 0.6000 - 5.3600 |
| Volume | 286,966 |
| Avg. Volume | 342,543 |
| Market Cap | 56.419M |
| Beta (3Y Monthly) | 2.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5240 |
| Earnings Date | Feb 28, 2018 - Mar 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.33 |
- PR Newswire•18 days ago
CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10
SEATTLE , April 3, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18 th Annual Needham Healthcare Conference ...
- Associated Press•last month
CTI BioPharma: 4Q Earnings Snapshot
On a per-share basis, the Seattle-based company said it had profit of 1 cent. The biotechnology company posted revenue of $14.1 million in the period. For the year, the company reported that its loss narrowed ...
- PR Newswire•last month
CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
SEATTLE , March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018 . "The Company is focused ...
- PR Newswire•last month
CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19
SEATTLE , March 12, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at Oppenheimer's 29 th Annual Healthcare Conference ...
- American City Business Journals•2 months ago
CTI BioPharma ups CEO pay as stock hovers near record low
The compensation hike comes at a time when CTI is cutting staff and subleasing extra office space in a bid to salvage its pipeline of cancer drug candidates.
- PR Newswire•2 months ago
CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27
SEATTLE , Feb. 20, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare ...
- American City Business Journals•2 months ago
CTI BioPharma collects $10M payment for former chemotherapy drug
The injection of funds comes at a critical time for CTI, which cut about half of its workforce in December as part of a restructuring plan.
- PR Newswire•2 months ago
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
SEATTLE , Feb. 11, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement ...
- American City Business Journals•2 months ago
Ex-CTI BioPharma CEO seeks startup funds as yacht lawsuit dismissed
Dr. James Bianco has faced multiple debt collection and class action lawsuits since stepping down as CEO of CTI BioPharma in late 2016.
- PR Newswire•3 months ago
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
SEATTLE, Feb. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis. The decision follows recent interactions with the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), during which the Company learned that the committee was likely to formally adopt a negative opinion in its evaluation of the application. The Company is continuing to develop pacritinib for both U.S. and European registration as a treatment for myelofibrosis patients with severe thrombocytopenia. CTI plans to seek scientific guidance from the EMA before beginning the planned Phase 3 study, having already discussed the protocol design with the FDA last month. The Phase 3 trial is expected to begin enrollment in the third quarter of 2019.
- PR Newswire•4 months ago
CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib
The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 following a meeting with the U.S. Food and Drug Administration (FDA). Topline efficacy and safety data are expected in the third quarter of 2019, with the new Phase 3 study targeted to commence enrollment in the third quarter of 2019.
- PR Newswire•4 months ago
CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
SEATTLE, Dec. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) announced today that it has received input from the U.S. Food and Drug Administration (FDA) at a recent Type C meeting on key elements of the design of a new randomized Phase 3 study of pacritinib in adult patients with myelofibrosis (primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis) and who have severe thrombocytopenia (as defined by patients with platelet counts of less than 50,000 per microliter), an indication that has been recognized by the medical community as an important unmet medical need.
- American City Business Journals•4 months ago
As CTI BioPharma restructures, former CEO James Bianco launches startup
It's one of two cancer drug startups that Dr. James Bianco has been linked to since leaving CTI BioPharma more than two years ago.
- Benzinga•4 months ago
The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 13) Kezar Life Sciences Inc (NASDAQ: KZR ) Down In The Dumps ...
- American City Business Journals•4 months ago
CTI BioPharma lays off half of workforce to save cash for lead drug trial
It’s CTI's latest attempt to salvage its pipeline of cancer drug candidates and reinvent the Seattle-based biotech after its co-founder and longtime CEO Dr. James Bianco stepped down in late 2016.
- PR Newswire•4 months ago
CTI BioPharma Announces Restructuring Plan
SEATTLE, Dec. 13, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) announced today a restructuring plan to improve efficiencies and reduce costs within the organization. As part of this plan, workforce reductions have been implemented that impact approximately 50 percent of the total number of the Company's employees. Cost savings of approximately $20 million primarily associated with reduced employee costs are expected over three years.
- PR Newswire•5 months ago
CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency
SEATTLE, Nov. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that the Company has received a second round of questions related to the Day 180 List of Outstanding Issues, for the marketing authorization application (MAA) for pacritinib, from the European Medicines Agency (EMA). The Company plans to submit responses to the EMA, which will include data from the ongoing open label PAC203 trial, by the end of the year.
- GlobeNewswire•5 months ago
Detailed Research: Economic Perspectives on Jason Industries, XBiotech, Dynatronics, Evolving, CTI BioPharma, and Charles & Colvard — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•6 months ago
CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -30.00% and 20.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•6 months ago
CTI BioPharma: 3Q Earnings Snapshot
On a per-share basis, the Seattle-based company said it had a loss of 26 cents. The biotechnology company posted revenue of $723,000 in the period. The company's shares closed at $1.71. A year ago, they ...
- PR Newswire•6 months ago
CTI BioPharma Reports Third Quarter 2018 Financial Results
-Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time- SEATTLE , Nov. 1, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the third quarter ...
- PR Newswire•6 months ago
CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018
SEATTLE , Oct. 25, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2018 financial results on Thursday, November ...
- Zacks•7 months ago
Is the Options Market Predicting a Spike in CTI BioPharma (CTIC) Stock?
Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.
- PR Newswire•7 months ago
CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review
SEATTLE, Oct. 1, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that following a planned second interim data review of the PAC203 study by the Independent Data Monitoring Committee (IDMC), the study will continue to the full enrollment of 150 patients. The IDMC did not identify significant drug- or dose-related safety concerns and specifically did not identify any concerns around hemorrhagic or cardiac toxicity.
- PR Newswire•7 months ago
CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3
SEATTLE , Sept. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare ...
